ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

utreglutide

Also written as “GL0034 Dose Level 1”, “GL0034 Dose Level 2” and “GL0034 Dose Level 3”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by Sun Pharmaceutical Industries.

Furthest: phase 2, since Dec 5, 20252 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sun Pharmaceutical Industries22 open or runningphase 2since Dec 5, 2025Dec 5, 2025Apr 2027phase 2 · NCT07282743

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 25, 2022Named utreglutideINNProposed as its International Nonproprietary Name in WHO's List 126
  2. Dec 5, 2025First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT07282743 · 285 planned · United States, India
  3. Jan 27, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07385547 · 40 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07282743

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07385547Diabetes Mellitus, Type 2 · United States1RecruitingSep 202640
NCT07282743Diabetes Mellitus, Type 2 · United States, India2RecruitingApr 2027285

How it is read

Names in the registry

  • “GL0034 Dose Level 1”, 1 entry
  • “GL0034 Dose Level 2”, 1 entry
  • “GL0034 Dose Level 3”, 1 entry
  • “GL0034 Dose Level 4”, 1 entry
  • “GL0034 Dose Level 5”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.